Concepedia

N. Colombo

NC

Statistics

Publications

4

Citations

179

H-Index

4

Active since

2017

Affiliations

European Institute of Oncology(Current)

The European Academy of Gynaecological Surgery

Merck & Co., Inc., Rahway, NJ, USA (United States)

University of Lübeck

University Hospital Schleswig-Holstein

N. Colombo is an author at European Institute of Oncology specializing in gynecologic oncology, medicine, and oncology.

Publications per year

2017–2025

4

Publications

4

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer

Toon Van Gorp, David Cibula, Weiguo Lv et al. · Annals of Oncology · 2024 · 82 citations · Full text

, , +4

Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study

Eric Pujade‐Lauraine, J.A. Ledermann, R. T. Penson et al. · Gynecologic Oncology · 2017 · 45 citations

, , +16

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

Philipp Harter, Christian Marth, Marie‐Ange Mouret‐Reynier et al. · Annals of Oncology · 2024 · 31 citations · Full text

, , +14

LBA3 Pembrolizumab vs placebo plus weekly paclitaxel ± bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65/KEYNOTE-B96 study

N. Colombo, E. Zsiros, A. Sebastianelli et al. · Annals of Oncology · 2025 · 21 citations · Full text

, , +16

1–4 of 4